Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/19/21 → 8/24/23 |
Funding
- AstraZeneca Pharmaceuticals LP (domestic): $21,830.00
A Phase 1/2a, Open-Label, Multicentre Study To Evaluate The Safety, Pharmacokinetics, And Preliminary Efficacy Of Subcutaneous Durvalumab In Patients With Non-Small Cell And Small Cell Lung Cancer -- SCope-D1
- Arnold, Susanne (PI)